Siemens to Acquire CTI Molecular Imaging

Siemens Medical Solutions USA (Erlangen, Germany) and CTI Molecular Imaging, Inc. (Knoxville, TN, USA) have entered into a merger agreement under which Siemens will acquire CTI. CTI is a leading supplier of products and services for positron emission tomography (PET) systems. The acquisition will include all the businesses of CTI Molecular Imaging, including PET systems, PETNET systems, Mirada systems, molecular technologies, and Concord Microsystems.

Under the terms of the agreement, Siemens will commence a cash tender offer to acquire all of the outstanding shares of CTI stock at a price of U.S.$20.50 per share. Following the completion of the tender offer, any remaining shares of CTI stock will be acquired in a merger at the same price per share. With this acquisition, Siemens continues to strengthen its commitment to molecular imaging development, technologic innovation, and the creation of new technologies that will advance the diagnosis and treatment of disease.

Michael Reitermann, president of Siemens Medical Solutions Nuclear Medicine Division, noted, "Molecular medicine will result in more individualized and more effective diagnosis and therapy. CT Molecular Imaging has been actively engaged in next-generation molecular diagnostics research, and the development will enable Siemens to strengthen and broaden our capabilities in molecular imaging, and define new standards within the industry.”





Related Links:
Siemens Medical Solutions
CTI Molecular Imaging